Overview

Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)

Status:
Terminated
Trial end date:
2018-12-24
Target enrollment:
Participant gender:
Summary
While some authors recommend diuretics as the first treatment to initiate for symptoms caused by malignant ascites (MA), their prescription is variable. No randomized, controlled study has assessed their benefit in this context. According to literature, diuretics may bring relief in about 40% of cases, regardless of primary tumor. The purpose of our study is to assess the effectiveness of diuretic treatment according to Serum Ascites Albumin Gradient (SAAG) measured before treatment. Judgment criteria is the time elapsed between recurrent MA that requires paracentesis. The investigators will also examine whether SAAG and serum levels of renin and aldosterone can predict symptom response to diuretics.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Oscar Lambret
Collaborator:
National Cancer Institute, France
Treatments:
Diuretics
Furosemide
Spironolactone